Chelsea tumbles on Northera study revision, likely resubmission delay
This article was originally published in Scrip
Executive Summary
Shares of Chelsea Therapeutics fell as low as 15.3% on 22 May after the Charlotte, North Carolina-based company said it intends to revise its initial plan and submit a modified proposal to the US FDA that calls for a change in the primary endpoint of a study it plans to submit in response to a rejection it received in March on its application for Northera (droxidopa).